Visceral fat and bevacizumab in metastatic colorectal cancer.
Jubb
A M
AM
D000230:Adenocarcinoma / Q000556:secondary*; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000473:pathology*; D006801:Humans; D050152:Intra-Abdominal Fat / Q000473:pathology*; D011379:Prognosis
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab